Showing results (11-20 of 358) with videos related to
Sort By:
Pageof 36
Journal of Thrombosis and Haemostasis : JTH|July 2, 2013
The role of the laboratory in treatment with new oral anticoagulantsT BaglinBritish Journal of Haematology|April 8, 1998
Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors. East Anglian Thrombophilia Study GroupC Baglin, K Brown, R Luddington, et al.Seminars in Vascular Medicine|June 17, 2004
Oral anticoagulant therapy in subjects with congenital or acquired thrombophiliaTrevor BaglinBritish Journal of Haematology|April 16, 2008
Venous thromboembolism in hospitalised patients: a public health crisis?Trevor BaglinJournal of Thrombosis and Haemostasis : JTH|July 28, 2009
What happens after venous thromboembolism?T BaglinBritish Journal of Haematology|August 14, 2013
Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxabanTrevor BaglinBritish Journal of Haematology|November 25, 1998
Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarinS Panneerselvam, C Baglin, W Lefort, et al.Lancet (London, England)|August 23, 2003
Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort studyTrevor Baglin, Roger Luddington, Karen Brown, et al.Journal of Thrombosis and Haemostasis : JTH|January 10, 2008
Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factorsT Baglin, C R Palmer, R Luddington, et al.Pageof 36